https://abbv-744inhibitor.com/....doublecortin-makes-i
To find modulators of AR-variant activity, we utilized a lysate-based small-molecule microarray assay and identified KI-ARv-03 as an AR-variant complex binder that reduces AR-driven transcription and proliferation in prostate cancer tumors cells. We deduced KI-ARv-03 to be a potent, selective inhibitor of CDK9, a significant cofactor for AR, MYC, along with other oncogenic transcription elements . Further optimization resulted in KB-0
Like
Comment
Share
